Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.
Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.